AU4327300A - Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension - Google Patents

Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Info

Publication number
AU4327300A
AU4327300A AU43273/00A AU4327300A AU4327300A AU 4327300 A AU4327300 A AU 4327300A AU 43273/00 A AU43273/00 A AU 43273/00A AU 4327300 A AU4327300 A AU 4327300A AU 4327300 A AU4327300 A AU 4327300A
Authority
AU
Australia
Prior art keywords
compositions
methods
vascular disease
pulmonary hypertension
peripheral vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43273/00A
Inventor
Michael D. Bentley
Martine Rothblatt
Robert Shorr
Xuan Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Therapeutics Corp
Original Assignee
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Therapeutics Corp filed Critical United Therapeutics Corp
Publication of AU4327300A publication Critical patent/AU4327300A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C07D307/937—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans with hydrocarbon or substituted hydrocarbon radicals directly attached in position 2, e.g. prostacyclins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0075—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system
    • C07C405/0083—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a condensed ring system which is only ortho or peri condensed, e.g. carbacyclins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU43273/00A 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension Abandoned AU4327300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12725599P 1999-03-31 1999-03-31
US12725499P 1999-03-31 1999-03-31
US60127254 1999-03-31
US60127255 1999-03-31
PCT/US2000/008240 WO2000057701A1 (en) 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Publications (1)

Publication Number Publication Date
AU4327300A true AU4327300A (en) 2000-10-16

Family

ID=26825478

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43273/00A Abandoned AU4327300A (en) 1999-03-31 2000-03-29 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension

Country Status (7)

Country Link
EP (1) EP1164846A1 (en)
JP (1) JP2003523935A (en)
KR (1) KR20020012169A (en)
CN (1) CN1354622A (en)
AU (1) AU4327300A (en)
CA (1) CA2359652A1 (en)
WO (1) WO2000057701A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
EP2792353B1 (en) * 2003-05-22 2018-02-28 United Therapeutics Corporation Polymorph of Treprostinil diethanolamine salt
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
US8765813B2 (en) 2003-12-16 2014-07-01 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
EP2329825B1 (en) * 2005-03-04 2015-10-07 Sucampo AG Method and composition for treating peripheral vascular diseases
WO2013024052A1 (en) * 2011-08-12 2013-02-21 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
JP2014522878A (en) * 2011-08-12 2014-09-08 アセンディス ファーマ エー／エス Prostacyclin sustained release composition
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CN105164098A (en) 2013-03-14 2015-12-16 联合治疗公司 Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp Salts of treprostinil
ES2676447T3 (en) 2013-03-25 2018-07-19 United Therapeutics Corporation Manufacturing process of prostacyclin compounds with binding thiol and pegylated forms
MX2020004912A (en) * 2013-10-25 2021-05-21 Insmed Inc Prostacyclin compounds, compositions and methods of use thereof.
CN106573066A (en) 2014-06-13 2017-04-19 联合治疗学有限公司 Treprostinil formulations
EP3209415B1 (en) 2014-10-20 2020-02-19 United Therapeutics Corporation Synthesis of intermediates for producing prostacyclin derivatives
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) * 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US20180153847A1 (en) 2016-09-26 2018-06-07 United Therapeutics Corporation Treprostinil prodrugs
SG10202100951SA (en) 2016-11-21 2021-03-30 Nanostring Technologies Inc Chemical compositions and methods of using same
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
MX2021013329A (en) 2019-04-29 2022-03-17 Insmed Inc Dry powder compositions of treprostinil prodrugs and methods of use thereof.
EP4017588A1 (en) 2019-08-23 2022-06-29 United Therapeutics Corporation Treprostinil prodrugs
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Treprostinil for use in the treatment of interstitial lung disease
CA3180230A1 (en) 2020-06-09 2021-12-16 Hitesh Batra Fumaryl diketopiperidine prodrugs of treprostinil
WO2022132655A1 (en) 2020-12-14 2022-06-23 United Therapeutics Corporation Methods of treating disease with treprostinil prodrugs
CN117479946A (en) 2021-03-03 2024-01-30 联合治疗公司 Dry powder compositions containing treprostinil and its prodrug and further comprising (E) -3,6-bis [4- (N-carbonyl-2-propenyl) amide butyl ] -2,5-diketopiperazine (FDKP)
WO2023154705A1 (en) 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy

Also Published As

Publication number Publication date
JP2003523935A (en) 2003-08-12
CN1354622A (en) 2002-06-19
KR20020012169A (en) 2002-02-15
EP1164846A1 (en) 2002-01-02
WO2000057701A1 (en) 2000-10-05
CA2359652A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
AU4327300A (en) Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU5963900A (en) Muteins of bilin-binding protein
AUPR638101A0 (en) Composition and method for treatment of disease
AU2268401A (en) Novel succinate compounds, compositions and methods of use and preparation
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU7743100A (en) Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
HK1042247A1 (en) Use of benzazepine-n ethanoic acid derivatives forpreparation of medicament for treating pulmonary hypertension.
AU2001257406A1 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
AU5780398A (en) Pharmaceutical composition for treatment of heart disease based on cardiac hypertrophy
AU1953701A (en) Methods and compositions for treatment of inflammatory disease
AU1878201A (en) Composition for the treatment of damaged tissue
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
AU2001267404A1 (en) Novel compounds for the treatment of inflammatory and cardiovascular diseases
AU4228000A (en) Methods and compositions for the treatment and prevention of lung disease
AUPP870999A0 (en) Method of treatment of equine disease
AU7670700A (en) Method for improving the stay-on properties of cosmetic compositions
AU4450100A (en) 225Ac-heha and related compounds, methods of synthesis and methods of use
AU3757200A (en) Treatment of pulmonary hypertension
AU8874198A (en) Antisense treatment of pulmonary hypertension
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase